Middle East and Africa Alpha-Glucosidase Inhibitors Market Size (2024 - 2029)

The Middle East and Africa Alpha-Glucosidase Inhibitors Market is experiencing growth driven by the increasing prevalence of diabetes, which is exacerbated by lifestyle changes in the region. The rising demand for diabetes management solutions, particularly in the context of COVID-19's impact on diabetic patients, is contributing to the expansion of this market. Governments in the region have implemented various strategies to address these health challenges, further influencing the market dynamics. The market's growth is particularly notable in African countries, where a significant portion of the global diabetes population resides, highlighting the region's critical role in the overall market landscape.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research General Pharmaceuticals Research Inhibitors Research Alpha-Glucosidase Inhibitors Market in MEA Market Size

Market Size of Middle East and Africa Alpha-Glucosidase Inhibitors Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Middle East And Africa Alpha-Glucosidase Inhibitors Market Summary
Study Period 2018 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2018 - 2022
CAGR 3.60 %

Major Players

Middle East and Africa Alpha-Glucosidase Inhibitors Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

MEA Alpha-Glucosidase Inhibitors Market Analysis

The Middle-East and Africa Alpha-Glucosidase Inhibitors Market size is estimated at USD 57.37 million in current year, and is expected to reach USD 68.46 million by forecast year, growing at a CAGR of 3.60% during the forecast period.

COVID-19 and diabetes have a significant impact on public health in the Middle East and Africa, as well as elsewhere. Diabetes has been linked to an increased risk of fatal infections and severe infections in COVID-19 patients. Because diabetes is one of the most common health problems in the Middle East and Africa, the current study focused on understanding the epidemiology of COVID-19 in diabetics and the strategies put in place by governments to mitigate its impact. In light of the importance and necessity of the epidemic, countries in the Middle East and Africa have implemented a number of preventative and control measures.

The Middle East and African region have witnessed an alarming increase in the prevalence of diabetes, in recent years, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels. Over the past few decades, african countries have witnessed a rapid increase in diabetes patients, especially those with type 2 diabetes. Developing countries have more than 70% of the global diabetes population. The africans anticipated to experience considerable growth due to a more geriatric population and rising prevalence of diabetes mainly due to the enhanced stress level, sedentary lifestyles, smoking, and excessive consumption of alcohol that elevates the body's sugar levels have led to the growth of the market.

This is driving the demand for Alpha-Glucosidase Inhibitors Market in Middle-East and Africa, thereby driving the market in focus during the forecast period.

MEA Alpha-Glucosidase Inhibitors Industry Segmentation

Inhibitors of alpha-glucosidase prevent the small intestine from absorbing carbohydrates. They compete with one another to prevent the enzymes that change complicated, non-absorptive carbohydrates into simple, absorbable ones. The glucoamylase, sucrase, maltase, and isomaltase enzymes are among them. The Middle East and Africa alpha-glucosidase inhibitors market is segmented by geography (Iran, Saudi Arabia, Egypt, Oman, South Africa, and the rest of the Middle East and Africa). The report offers the value (in USD) and volume (in units) for the above segments. We will provide a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.

Drug
Alpha-glucosidase Inhibitors
Geography
South Africa
Saudi Arabia
Oman
Egypt
Iran
Rest of Middle-East and Africa
Need A Different Region Or Segment?
Customize Now

Middle East and Africa Alpha-Glucosidase Inhibitors Market Size Summary

The Middle East and Africa alpha-glucosidase inhibitors market is poised for growth, driven by the rising prevalence of diabetes in the region. This increase is largely attributed to lifestyle changes, leading to a higher incidence of type 2 diabetes, which constitutes the majority of diabetes cases in the area. The market is influenced by the need for effective management of diabetes-related complications, as patients require ongoing monitoring and intervention to maintain blood glucose levels. The demand for alpha-glucosidase inhibitors is expected to rise as these medications play a crucial role in managing diabetes, particularly in countries like Saudi Arabia, where government initiatives aim to reduce the disease's prevalence through preventive measures and healthcare reforms.

The market landscape is characterized by a fragmented presence of key manufacturers such as Bayer, SunPharma, Pfizer, and Takeda, who are actively involved in research and development to enhance diabetes treatment options. The focus on drug repurposing and the investigation of FDA-approved drugs for glucosidase inhibition highlight the ongoing efforts to innovate within the market. Additionally, regulatory actions, such as price fixing by the National Pharmaceutical Pricing Authority in India, reflect the broader economic considerations impacting the market. As the region continues to address the challenges posed by diabetes and its complications, the alpha-glucosidase inhibitors market is expected to expand, supported by both governmental and private sector initiatives aimed at improving healthcare access and quality.

Explore More

Middle East and Africa Alpha-Glucosidase Inhibitors Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Drivers

    3. 1.3 Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. Market Segmentation

    1. 2.1 Drug

      1. 2.1.1 Alpha-glucosidase Inhibitors

    2. 2.2 Geography

      1. 2.2.1 South Africa

      2. 2.2.2 Saudi Arabia

      3. 2.2.3 Oman

      4. 2.2.4 Egypt

      5. 2.2.5 Iran

      6. 2.2.6 Rest of Middle-East and Africa

Middle East and Africa Alpha-Glucosidase Inhibitors Market Size FAQs

The Middle East and Africa Alpha-Glucosidase Inhibitors Market is projected to register a CAGR of 3.60% during the forecast period (2024-2029)

Takeda, Pfizer, Bayer, SunPharma and Glenmark are the major companies operating in the Middle East and Africa Alpha-Glucosidase Inhibitors Market.

MEA Alpha-Glucosidase Inhibitors Market Report Snapshots

Middle East And Africa Alpha-Glucosidase Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)